XClinical GmbH, Munich, Germany – February 15th, 2011 – XClinical, European vendor of innovative software products for eClinical trials, well known for its innovative and user-friendly CDISC ODM-certified EDC software suite MARVIN, had a very successful and innovative business year.
Extended workforce
Constant growth in the past years and the successful market relaunch of the STUDY COMPOSER as a standalone software tool at the beginning of 2010 has allowed XClinical to adapt its staffing situation to the favourable conditions and thus six new colleagues joined the corporate workforce. “The enlarged team enables us to develop our products more target-oriented and to support our customers even more comprehensively,” comments Dr. Philippe Verplancke, CEO and QM at XClinical. The changes within XClinical were also made visible to the outside: Marketing Department renewed the Corporate Design including the relaunch of the company website and existing marketing materials, reworked the company’s concept for conference appearance and implemented an official newsletter.
Continuous growth
Despite – or even because of – the efforts of integrating new staff into an existing team and existing workflows, XClinical experienced continuous growth and was able to expand its existing markets in the US, Europe and Asia. Both new and existing clients started about 45 new projects in 2011. To a large extend, this is owed to the company’s frequent participation in international pharmaceutical and data management events to establish contact with the industry worldwide. “It’s not only that we attend those conferences as exhibitors and speakers. Last year we also hosted the 2nd XClinical End-to-End Workshop. In our opinion, being a software provider also means sharing previous experience.” says Dr. Verplancke. “And it also means providing a platform for our clients to share their experience and to enter into dialogue with us. Last year we hosted the 6th XClinical User Meeting, which again was extremely successful.”
Affirmation of work by FDA’s future development plans
Last year XClinical received affirmation of its work by the FDA (Federal Drug Association). In the second half of 2010 the FDA announced to intensify the development of a data standard for electronic submission. XClinical experts see their opinion reconfirmed by the FDA’s approach to use CDISC standards for e-submission in the foreseeable future. “The FDA’s plan to reconsider the CDISC ODM standard in particular for e-submission really validates our approach. Our EDC System MARVIN and our eCRF design tool STUDY COMPOSER are both CDISC-compliant,” claims the CEO of XClinical.
Future Prospects
In 2011, XClinical aims at maintaining last year’s success. With the planned recruitment of more new employees, particularly in the software development department, XClinical strives to meet market requirements, develop new products and refine existing ones.
Motivated by last year’s workshop success, XClinical is planning to host a workshop specially designed for CEOs of contract research organizations and will also reissue the End-To-End workshop. ”Having dedicated this much energy to the restructuring and expansion of our team, we have built the foundations for the expansion of last year’s success”, says Dr. Verplancke.
You must be logged in to post a comment Login